Europe's Medicine Agency Increases Lemtrada Restrictions

Lemtrada Stroke Lawsuit News

Lemtrada now carries even greater restrictions due to the drug's potential to cause stroke, heart attack, and sudden death

Monday, November 4, 2019 - Lemtrada is one of the most effective drugs in treating relapse remitting multiple sclerosis (RRMS), however, the drug's side effects are so severe that the European Medicines Agency has announced that a new level of restrictions is to be placed on using the drug. "Lemtrada (alemtuzumab) should be given only to people with highly active relapsing-remitting multiple sclerosis (RRMS) according to a review carried out by the European Medicines Agency's (EMA) drug safety committee." The EMA now restricts the use of Lemtrada to cases of highly active RRMS where no other drug has worked or if the patient's multiple sclerosis is rapidly worsening and also to those having at least two relapses in the previous 12 months that include brain damage occurring. Lemtrada stroke lawsuits are handled by top national attorneys with vast experience handling pharmaceutical litigations and offer a free consultation.

According to MS in a November 1, 2019 article. This new level of warning is in addition to the previous instructions that Lemtrada is to be used only as a drug of last resort after two or more other MS modification drugs have failed. Lemtrada restrictions continue and include screening potential patients for preexisting conditions that would put them at greater risk. Lemtrada may not be given to people with heart conditions, circulatory problems, blood clotting difficulty or autoimmune disease, among other conditions. The EMA's investigation of Lemtrada originated as a result of reports of patients experiencing strokes heart attacks blood circulation and other severe and life-threatening side effects. Within 1 to 3 days of receiving a Lemtrada infusion. Reports to the EMA state: "rare but serious effects, including deaths, from immune-mediated conditions (caused by the body's defense system not working properly) and serious heart, circulation, and bleeding disorders, including stroke. Immune-mediated conditions can occur many months after treatment while serious disorders of the heart, circulation, and bleeding may develop within days of receiving Lemtrada."

Relapse remitting multiple sclerosis is a heinous condition where the body's immune system attacks and destroys the protective sheathing that covers nerve tissue. The disease is characterized by intermittent attacks followed by periods of remission. Over time the RRMS attacks increase in severity, duration, and frequency. Relapse remitting multiple sclerosis patients with none of the preexisting conditions listed above and have tried and failed with 2 or more previous therapies may receive Lemtrada in a series of daily infusions delivered in two stages. The first stage consists of five daily infusion sessions and the second stage of three infusions sessions one year later. Lemtrada has been moderately successful in decreasing the progression of the disease. The third round of Lemtrada infusion may be needed in extreme cases.

Alemtuzumab (Lemtrada) is a monoclonal antibody that destroys a protein found in the immune system. According to, the most common, non-life threatening side effects of Lemtrada include rashes, headaches, nausea, urinary tract infections, fatigue, insomnia, back pain, and diarrhea. Lemtrada patients are required to monitored during and after receiving treatment for signs of a stroke or heart attack.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.